Bromodomain Containing Protein 2 - Pipeline Review, H1 2020
Bromodomain Containing Protein 2 - Pipeline Review, H1 2020
SUMMARY
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene.
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Immunology, Musculoskeletal Disorders and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Fibrosis, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease), Myelofibrosis, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Small-Cell Lung Cancer, Systemic Lupus Erythematosus and Vitiligo.
The latest report Bromodomain Containing Protein 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene.
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Immunology, Musculoskeletal Disorders and Respiratory which include indications Atopic Dermatitis (Atopic Eczema), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Fibrosis, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease), Myelofibrosis, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Small-Cell Lung Cancer, Systemic Lupus Erythematosus and Vitiligo.
The latest report Bromodomain Containing Protein 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
- The report reviews Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
Ningbo Wenda Pharma
Zenith Epigenetics Ltd
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles
ABBV-744 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-95775 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-0610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NHWD-870 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-19796 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-20798 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-7770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QCA-570 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones
Featured News & Press Releases
Jan 07, 2020: Zenith Epigenetics receives US$5 million milestone payment from Newsoara
Dec 19, 2019: Zenith Epigenetics announces clinical advancement of ZEN-3694
Dec 09, 2019: Constellation Pharmaceuticals provides updated preliminary data from MANIFEST clinical trial with CPI-0610 in oral and poster presentations at ASH
Dec 02, 2019: Constellation Pharmaceuticals to host analyst/investor meeting at ASH to discuss updated preliminary data from the MANIFEST clinical trial with CPI-0610
Nov 06, 2019: FORMA announces poster presentation on FT-1101 at upcoming 2019 ASH Annual Meeting
Oct 10, 2019: Constellation Pharmaceuticals announces MANIFEST data updates will be provided in oral and poster sessions on December 9 at ASH
Jun 27, 2019: Zenith Epigenetics announces dosing of first patient in triple negative breast cancer trial with Pfizer
Jun 03, 2019: Interim data for CPI-0610 in MANIFEST clinical trial showed signals of clinical activity in Myelofibrosis patients
May 23, 2019: Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial
May 16, 2019: Constellation Pharmaceuticals provides interim update of data for CPI-0610 in ASCO and EHA abstracts
May 09, 2019: Nuevolution’s BET-BD1 selective inhibitor and candidate compound, NUE20798, shows positive effect on disease scoring and biomarker levels in an atopic dermatitis (eczema) mouse model
Mar 18, 2019: Zenith Epigenetics announces U.S. FDA clearance of investigational new drug application for ZEN-3694 in TNBC program
Feb 21, 2019: A Nuevolution BET-BD1 selective inhibitor shows potential anticancer effect with immunotherapy in a mouse model of colorectal cancer
Jan 03, 2019: Constellation Pharmaceuticals provides update on MANIFEST clinical trial of CPI-0610 in mlyelofibrosis
Nov 01, 2018: Constellation Pharmaceuticals receives FDA Fast Track Designation for CPI-0610 in treatment of Myelofibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
Ningbo Wenda Pharma
Zenith Epigenetics Ltd
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles
ABBV-744 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-95775 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-0610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NHWD-870 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-19796 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-20798 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NUE-7770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QCA-570 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones
Featured News & Press Releases
Jan 07, 2020: Zenith Epigenetics receives US$5 million milestone payment from Newsoara
Dec 19, 2019: Zenith Epigenetics announces clinical advancement of ZEN-3694
Dec 09, 2019: Constellation Pharmaceuticals provides updated preliminary data from MANIFEST clinical trial with CPI-0610 in oral and poster presentations at ASH
Dec 02, 2019: Constellation Pharmaceuticals to host analyst/investor meeting at ASH to discuss updated preliminary data from the MANIFEST clinical trial with CPI-0610
Nov 06, 2019: FORMA announces poster presentation on FT-1101 at upcoming 2019 ASH Annual Meeting
Oct 10, 2019: Constellation Pharmaceuticals announces MANIFEST data updates will be provided in oral and poster sessions on December 9 at ASH
Jun 27, 2019: Zenith Epigenetics announces dosing of first patient in triple negative breast cancer trial with Pfizer
Jun 03, 2019: Interim data for CPI-0610 in MANIFEST clinical trial showed signals of clinical activity in Myelofibrosis patients
May 23, 2019: Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial
May 16, 2019: Constellation Pharmaceuticals provides interim update of data for CPI-0610 in ASCO and EHA abstracts
May 09, 2019: Nuevolution’s BET-BD1 selective inhibitor and candidate compound, NUE20798, shows positive effect on disease scoring and biomarker levels in an atopic dermatitis (eczema) mouse model
Mar 18, 2019: Zenith Epigenetics announces U.S. FDA clearance of investigational new drug application for ZEN-3694 in TNBC program
Feb 21, 2019: A Nuevolution BET-BD1 selective inhibitor shows potential anticancer effect with immunotherapy in a mouse model of colorectal cancer
Jan 03, 2019: Constellation Pharmaceuticals provides update on MANIFEST clinical trial of CPI-0610 in mlyelofibrosis
Nov 01, 2018: Constellation Pharmaceuticals receives FDA Fast Track Designation for CPI-0610 in treatment of Myelofibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Boston Pharmaceuticals Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Constellation Pharmaceuticals Inc, H1 2020
Pipeline by Ningbo Wenda Pharma, H1 2020
Pipeline by Zenith Epigenetics Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Boston Pharmaceuticals Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Constellation Pharmaceuticals Inc, H1 2020
Pipeline by Ningbo Wenda Pharma, H1 2020
Pipeline by Zenith Epigenetics Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
Ningbo Wenda Pharma
Zenith Epigenetics Ltd
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
Ningbo Wenda Pharma
Zenith Epigenetics Ltd
